{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:32:54Z","timestamp":1777869174299,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"DOI":"10.7759\/cureus.108024","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:15:26Z","timestamp":1777554926000},"source":"Crossref","is-referenced-by-count":0,"title":["Survival Trends in Metastatic Renal Cell Carcinoma Across Therapeutic Eras and Histologic Subtypes"],"prefix":"10.7759","author":[{"given":"Sai Tharun Reddy","family":"Gopannagari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganisetti","family":"Divya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kesava Manikanta","family":"Achuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chadi","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh JJ","year":"2017","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, et al.. Renal cell carcinoma. Nat Rev Dis Primers. 2017, 3:17009. 10.1038\/nrdp.2017.9","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel RL","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023, 73:17-48. 10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"ref3","unstructured":"National Cancer Institute. Cancer stat facts: kidney and renal pelvis cancer. (2026). Accessed: April 05, 2026: https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1590\/0100-3984.2013.1927","article-title":"Renal cell carcinoma: histological classification and correlation with imaging findings","volume":"48","author":"Muglia VF","year":"2015","unstructured":"Muglia VF, Prando A. Renal cell carcinoma: histological classification and correlation with imaging findings. Radiol Bras. 2015, 48:166-74. 10.1590\/0100-3984.2013.1927","journal-title":"Radiol Bras"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-003-0039-2","article-title":"Metastatic renal cell carcinoma","volume":"4","author":"Flanigan RC","year":"2003","unstructured":"Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr Treat Options Oncol. 2003, 4:385-90. 10.1007\/s11864-003-0039-2","journal-title":"Curr Treat Options Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.04.44","article-title":"Survival outcomes for advanced kidney cancer patients in the era of targeted therapies","volume":"6","author":"Rao A","year":"2018","unstructured":"Rao A, Wiggins C, Lauer RC. Survival outcomes for advanced kidney cancer patients in the era of targeted therapies. Ann Transl Med. 2018, 6:165. 10.21037\/atm.2018.04.44","journal-title":"Ann Transl Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe G","year":"1995","unstructured":"Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995, 13:688-96. 10.1200\/JCO.1995.13.3.688","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer RJ","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, et al.. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007, 356:115-24. 10.1056\/NEJMoa065044","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer RJ","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, et al.. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018, 378:1277-90. 10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"key":"ref10","unstructured":"National Cancer Institute. SEER*Stat Databases: SEER November 2024 Submission, Incidence - SEER Research Data, 17 Registries, Nov 2024 Sub (2000-2022). (2026). Accessed: April 05, 2026: https:\/\/seer.cancer.gov\/data-software\/documentation\/seerstat\/nov2024\/."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini BI","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, et al.. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019, 380:1116-27. 10.1056\/NEJMoa1816714","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri TK","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, et al.. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021, 384:829-41. 10.1056\/NEJMoa2026982","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer R","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, et al.. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021, 384:1289-300. 10.1056\/NEJMoa2035716","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0005","article-title":"Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC\u00a0risk groups in metastatic renal cell carcinoma: a meta-analysis","volume":"13","author":"Rizzo A","year":"2021","unstructured":"Rizzo A, Mollica V, Santoni M, et al.. Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC\u00a0risk groups in metastatic renal cell carcinoma: a meta-analysis. Immunotherapy. 2021, 13:783-93. 10.2217\/imt-2021-0005","journal-title":"Immunotherapy"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2024.102639","article-title":"Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors","volume":"92","author":"Adhikari A","year":"2024","unstructured":"Adhikari A, Sapkota S, Gogia S, Kc O. Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors. Cancer Epidemiol. 2024, 92:102639. 10.1016\/j.canep.2024.102639","journal-title":"Cancer Epidemiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32060359","article-title":"Molecular genetics of renal cell carcinoma: a narrative review focused on clinical relevance","volume":"32","author":"Millan B","year":"2025","unstructured":"Millan B, Loebach L, Blachman-Braun R, Patel MH, Saini J, Linehan WM, Ball MW. Molecular genetics of renal cell carcinoma: a narrative review focused on clinical relevance. Curr Oncol. 2025, 32:359. 10.3390\/curroncol32060359","journal-title":"Curr Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00276-0","article-title":"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial","volume":"24","author":"Albiges L","year":"2023","unstructured":"Albiges L, Gurney H, Atduev V, et al.. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2023, 24:881-91. 10.1016\/S1470-2045(23)00276-0","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial","volume":"397","author":"Pal SK","year":"2021","unstructured":"Pal SK, Tangen C, Thompson IM Jr, et al.. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021, 397:695-703. 10.1016\/S0140-6736(21)00152-5","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4274","article-title":"The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt","volume":"30","author":"Royston P","year":"2011","unstructured":"Royston P, Parmar MK. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011, 30:2409-21. 10.1002\/sim.4274","journal-title":"Stat Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean A","year":"2018","unstructured":"M\u00e9jean A, Ravaud A, Thezenas S, et al.. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018, 379:417-27. 10.1056\/NEJMoa1803675","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.06.006","article-title":"Surgical safety of cytoreductive nephrectomy following sunitinib: results from the multicentre, randomised controlled trial of immediate versus deferred nephrectomy (SURTIME)","volume":"76","author":"De Bruijn RE","year":"2019","unstructured":"De Bruijn RE, Mulders P, Jewett MA, et al.. Surgical safety of cytoreductive nephrectomy following sunitinib: results from the multicentre, randomised controlled trial of immediate versus deferred nephrectomy (SURTIME). Eur Urol. 2019, 76:437-40. 10.1016\/j.eururo.2019.06.006","journal-title":"Eur Urol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/486296-survival-trends-in-metastatic-renal-cell-carcinoma-across-therapeutic-eras-and-histologic-subtypes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:15:28Z","timestamp":1777554928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/486296-survival-trends-in-metastatic-renal-cell-carcinoma-across-therapeutic-eras-and-histologic-subtypes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.108024","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}